Specifically, the p.R591 C, a clinically relevant PARP mutation found in an olaparib-resistant ovarian cancer patients promotes dissociation of PARP1 from the DNA damage site showing inefficient PARP trapping resulting in PARP resistance [81]. Here, PARP1 is linked to ovarian carcinoma.